TY - JOUR
T1 - Next-generation antibody therapeutics
T2 - Discovery, development and beyond: Highlights of the third annual conference of the chinese antibody society
AU - Zhang, Hongyu
AU - Deng, Mi
AU - Pei, Fen
AU - Wang, Shouye
AU - Ho, Mitchell
N1 - Funding Information:
Dr. Mitchell Ho’s work is supported by the Intramural Research Program of the National Institutes of Health, NCI and the Center for Cancer Research. The authors thank the conference speakers for reviewing the manuscript and Jessica Hong (NCI) for editorial assistance. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.
Publisher Copyright:
© The Author(s) 2019.
PY - 2019
Y1 - 2019
N2 - The Chinese Antibody Society (CAS) convened the third annual conference in Cambridge, Massachusetts, USA on April 7, 2019. More than 600 global members attended the meeting. The theme of this conference was Next-Generation Antibody Therapeutics: Discovery, Development and Beyond. The meeting covered a vast variety of topics including cancer immunotherapy, single-domain antibodies as well as bispecific antibodies, immunotoxins, transgenic mouse platforms for next-generation monoclonal antibody discovery and antibody chemistry, manufacturing and controls (CMCs). Two hot topics were comprehensively discussed by the prestigious panelists and hosts at the panel discussions during the conferences, i.e., bispecific antibodies and antibody CMC. Statement of Significance: The Chinese Antibody Society convened the third annual conference in Cambridge, Massachusetts, USA on 7 April 2019. The meeting covered a variety of topics, including cancer immunotherapy, single-domain antibody, bispecific antibody, immunotoxin, transgenic mouse platforms for next-generation monoclonal antibody discovery and antibody CMC.
AB - The Chinese Antibody Society (CAS) convened the third annual conference in Cambridge, Massachusetts, USA on April 7, 2019. More than 600 global members attended the meeting. The theme of this conference was Next-Generation Antibody Therapeutics: Discovery, Development and Beyond. The meeting covered a vast variety of topics including cancer immunotherapy, single-domain antibodies as well as bispecific antibodies, immunotoxins, transgenic mouse platforms for next-generation monoclonal antibody discovery and antibody chemistry, manufacturing and controls (CMCs). Two hot topics were comprehensively discussed by the prestigious panelists and hosts at the panel discussions during the conferences, i.e., bispecific antibodies and antibody CMC. Statement of Significance: The Chinese Antibody Society convened the third annual conference in Cambridge, Massachusetts, USA on 7 April 2019. The meeting covered a variety of topics, including cancer immunotherapy, single-domain antibody, bispecific antibody, immunotoxin, transgenic mouse platforms for next-generation monoclonal antibody discovery and antibody CMC.
KW - Antibody therapeutics
KW - Bispecific antibodies
KW - Chemistry manufacturing and Controls (CMC)
KW - Chinese Antibody Society;
KW - Immuno-oncology
KW - Immunotoxin
KW - Single-domain antibody
KW - Transgenic mouse platforms
UR - http://www.scopus.com/inward/record.url?scp=85100671684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100671684&partnerID=8YFLogxK
U2 - 10.1093/abt/tbz012
DO - 10.1093/abt/tbz012
M3 - Article
C2 - 31942535
AN - SCOPUS:85100671684
SN - 2516-4236
VL - 2
SP - 88
EP - 96
JO - Antibody Therapeutics
JF - Antibody Therapeutics
IS - 4
ER -